Halbreich U, Piletz J E, Carson S, Halaris A, Rojansky N
Department of Psychiatry, State University of New York at Buffalo 14215.
Biol Psychiatry. 1993 Nov 15;34(10):676-86. doi: 10.1016/0006-3223(93)90040-k.
An association between dysphoric premenstrual syndromes (PMS) and a lifetime history of major depressive disorders has previously been documented. Other studies have demonstrated an increase in the binding of radiolabeled imidazoline compounds to platelets of depressed patients. Clonidine and related imidazoline compounds interact with alpha 2 adrenoceptors to inhibit neuronal noradrenergic activity and in higher concentrations, they stimulate noradrenergic activity through their interaction with imidazoline receptors. Here we report increased 3H para-aminoclonidine binding to high affinity alpha 2 adrenoceptor sites as well as to nonadrenergic imidazoline binding sites in platelets of women with dysphoric PMS. This higher binding was most pronounced during the late-luteal-symptomatic phase of the menstrual cycle and, to a lesser degree, during the non-symptomatic mid-follicular phase. Binding to the imidazoline site distinguished women with dysphoric PMS from women with no such symptoms, was highly positively correlated with the severity of symptoms, and was negatively correlated with plasma levels of progesterone. These findings suggest that platelet imidazoline binding sites might be a biological marker for dysphoric states in PMS or for the vulnerability to develop them. These findings also point to a possible biological link between dysphoric PMS and major depressive disorders.
经前期烦躁障碍（PMS）与重度抑郁症的终生病史之间的关联此前已有记录。其他研究表明，放射性标记的咪唑啉化合物与抑郁症患者血小板的结合增加。可乐定及相关咪唑啉化合物与α2肾上腺素能受体相互作用以抑制神经元去甲肾上腺素能活性，而在较高浓度下，它们通过与咪唑啉受体的相互作用刺激去甲肾上腺素能活性。在此我们报告，经前期烦躁障碍女性血小板中3H-对氨基可乐定与高亲和力α2肾上腺素能受体位点以及非肾上腺素能咪唑啉结合位点的结合增加。这种更高的结合在月经周期的黄体晚期症状期最为明显，在无症状的卵泡中期也有一定程度的增加。与咪唑啉位点的结合可将经前期烦躁障碍女性与无此类症状的女性区分开来，与症状严重程度高度正相关，与血浆孕酮水平负相关。这些发现表明，血小板咪唑啉结合位点可能是经前期烦躁障碍烦躁状态或其易感性的生物学标志物。这些发现还指出了经前期烦躁障碍与重度抑郁症之间可能的生物学联系。
